“Controlling the Sound of Light”: New Review about Photoswitching Optoacoustic Imaging

The Future of Optoacoustic Labels

Optoacoustic imaging is utilizing sound that is generated following the absorption of light. While label-free imaging using only naturally occurring absorbers such as blood is already in clinical use, the integration of robust, engineered optoacoustic labels will enable researchers to visualize biological processes with unprecedented precision. Unlike traditional imaging labels, robust optoacoustic labels are engineered to withstand varying conditions and deliver consistent, high-quality signals. They can be activated or “switched” on and off using light or other energy sources, helping scientists to track dynamic processes in real-time with greater precision. These labels are crucial for advancing the use of optoacoustic imaging in both basic research and clinical applications.

The review explores novel techniques in signal modulation and synchronous detection, which utilize light or other forms of energy to achieve superior contrast and resolution. These advances are set to significantly enhance the capability to detect cellular or molecular signals at greater depths and with higher clarity than current optical methods allow.

Applications Beyond Microscopy

As optoacoustic imaging becomes more advanced, its applications are expected to expand, enabling more detailed studies of cellular and molecular contrast in tissues. The authors discuss potential systems and applications, positioning optoacoustic imaging as a crucial tool for researchers aiming to explore new biological frontiers, particularly in fields like cancer research, neuroscience, and regenerative medicine.

“The integration of advanced optoacoustic labels and novel switching technologies will help researchers push the boundaries of optical imaging, allowing them to study biological processes at depths and resolutions previously unattainable. These advancements will bring a “new sound” to biological optoacoustic imaging.”, says André C. Stiel, Group Leader at the Helmholtz Munich Bioengineering Center and Professor at the University of Regensburg.